BIVI
BioVie Inc.
Set alert
1.43 USD +0.05 +3.62%
1.38 Day range 1.49
0.964 52-week range 2.28
- YTD
- +23.28%
- 1 year
- -19.21%
- Open
- 1.39
- Prev close
- 1.38
- Mkt cap
- 12.42M
- Vol
- 105.82K
- Avg vol
- 4.59M
- EPS
- -3.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.38
- High
- 1.49
- Forward P/E
- -0.49
- Beta
- 0.90
- Short ratio
- 0.15
- Inst. own
- 9.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 10, 2025
- 50-d avg
- 2.66
- 200-d avg
- 3.68
- 1y target
- 5.00
Key statistics
- Market cap
- 38.20M
- Enterprise value
- 7.49M
- Trailing P/E
- 0.00
- Forward P/E
- -0.49
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.86
- EPS (TTM)
- -5.08
- Beta
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -18.78M
- Total cash
- 23.84M
- Total debt
- 6.11M
- Return on equity
- -208.26%
- Shares outstanding
- 17.77M
- Short % of float
- 12.52%
- 50-day average
- 2.66
- 200-day average
- 3.68
Analyst view
Consensus: none
Price target (mean) 5.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 10, 2025
Expected Feb 10, 2025. Consensus EPS estimate 0.00.
Financials — quick view
BIVI Revenue — quarterly 0
BIVI Net income — quarterly -5.65M
BIVI EPS — quarterly -0.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.70 | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | -6.60 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -2.00 | — | — |
| Feb 12, 2024 | Dec 1, 2023 | -3.20 | -2.20 | +1.00 | +31.25% |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | -2.90 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 1, 2024 | ThinkEquity | init | — | Buy |
| Nov 30, 2023 | Oppenheimer | main | Outperform | Outperform |
| Aug 22, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jul 18, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| May 17, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| May 17, 2023 | Oppenheimer | reit | Outperform | Outperform |
About BioVie Inc.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bioviepharma.com
News
- BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual Workshop
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- BioVie reports positive Phase 2 Parkinson's data for bezisterim
- BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meeting
- BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups
- BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
- BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting
- BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
- BioVie Highlights Bezisterim Phase II Data, Eyes FDA Path for Phase III Trials
- BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
Your note
Sign in to keep a note on BIVI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERMAN RICHARD JAY | Director | Stock Award(Grant) | Nov 8, 2023 | 69,235 |
| DO CUONG VIET | Chief Executive Officer | Stock Award(Grant) | Jun 23, 2024 | 0 |
| GORLIN STEVEN | Director | Sale | Nov 30, 2023 | 46,358 |
| HARIRI ROBERT J | Director | Stock Award(Grant) | Nov 8, 2023 | 42,254 |
| KIM JOANNE WENDY | Chief Financial Officer | Stock Award(Grant) | Jun 23, 2024 | 93,940 |
| PALUMBO JOSEPH M | Officer | Stock Award(Grant) | Jun 23, 2024 | 119,196 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 0.32% | 56,837 | 122.20K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.21% | 38,174 | 82.07K | Sep 29, 2024 |
| Zullo Investment Group, Inc. | 0.14% | 25,000 | 53.75K | Sep 29, 2024 |
| Cerity Partners LLC | 0.10% | 17,230 | 37.04K | Sep 29, 2024 |
| United Capital Management of KS, Inc. | 0.06% | 10,000 | 21.50K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.02% | 4,300 | 9.24K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.23% | 41,509 | 89.24K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.12% | 21,816 | 46.90K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 14,764 | 31.74K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 5,158 | 11.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 1,855 | 3.99K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,295 | 4.93K | Oct 30, 2024 |